UCI Study: Infection Risks Found in Antibody-Drug Conjugate Therapy

As the landscape of targeted cancer treatment evolves, antibody-drug conjugates (ADCs) have emerged as a cornerstone of modern oncology. Designed to deliver potent chemotherapy directly to malignant cells while sparing healthy tissue, ADCs have significantly improved outcomes for patients with breast and blood cancers.

However, a new large-scale study led by researchers at the University of California, Irvine (UCI), serves as a critical reminder that these targeted therapies are not without systemic risks — specifically regarding hematologic toxicities and life-threatening infections.

For oncology nurses, who are on the front lines of infusion administration and symptom management, the findings published in the journal Cancers highlight a pressing need for heightened vigilance. The study, which analyzed real-world data from 3,511 patients across six UC medical centers between 2012 and 2024, found that certain ADC therapies are associated with dangerously low levels of infection-fighting white blood cells.

The reality of real-world data

While clinical trials provide the necessary evidence for drug approval, they often occur within highly controlled environments with specific patient populations. This study, led by Alexandre Chan, PharmD, MPH, professor and chair of clinical pharmacy practice at UCI, utilized the University of California Health Data Warehouse to examine how 10 commonly used FDA-approved ADCs perform in a broader, more diverse patient population.

According to a news release issued by UCI, Chan stated: “Our findings demonstrate that while antibody-drug conjugates offer tremendous promise for cancer patients, clinicians must remain vigilant about potentially serious hematologic toxicities.” He emphasized that real-world data provides a clearer picture of how these therapies affect patients who may have comorbidities not always represented in trials.

Identifying severe neutropenia and its complications

The research team identified substantial rates of severe neutropenia and febrile neutropenia, a medical emergency characterized by fever and a lack of white blood cells to fight off infection. The consequences of these side effects are significant, often leading to hospitalizations and admissions to intensive care units.

One of the most vital takeaways for nursing practice is the wide variation in risk depending on the specific agent used. The study found that infection-related complications were not uniform across the ADC class; rather, the risk levels were highly dependent on the specific drug being administered. This suggests that nurses must be familiar with the unique toxicity profile of each ADC in their clinic's formulary.

Recognizing high-risk patient profiles

In addition to the drugs themselves, the UCI study identified specific patient-related factors that increased the likelihood of complications. Patients with underlying anemia or immunodeficiency disorders were found to be at a significantly higher risk for hematological toxicities.

For oncology nurses, this underscores the importance of a thorough baseline assessment. When preparing a patient for ADC therapy, nursing staff should pay close attention to:

• Pre-existing hematologic conditions, such as chronic anemia.
• The patient’s immune status and history of prior infections.
• Baseline white blood cell and neutrophil counts before every infusion cycle.

The nursing role: Proactive monitoring and care

As these targeted therapies become more prevalent in standard care, the oncology nurse’s role in proactive monitoring and management becomes paramount. The study highlights the potential for earlier monitoring or preventive interventions to improve patient outcomes.

As noted in the news release, Chan remarked: “As these targeted therapies become more widely used, understanding and anticipating side effects becomes increasingly important.”

By anticipating these side effects, nurses can implement supportive care measures, such as the administration of growth factors or patient education on infection prevention, before a minor side effect escalates into a life-threatening hospitalization.

Nursing interventions should focus on educating patients to recognize early signs of febrile neutropenia, such as even a low-grade fever, chills, or malaise. Given that the study linked ADCs to ICU-level complications, the window for intervention is often narrow.

The UCI-led study serves as a call to action for the oncology community. While ADCs represent a leap forward in precision medicine, the risk of severe neutropenia is a reality that requires diligent clinical oversight. By leveraging large-scale health system data, researchers have provided oncology nurses with the insights needed to identify high-risk patients and advocate for the supportive care necessary to keep them safe during treatment.

References

1. University of California, Irvine. UC Irvine study identifies serious infection risks linked to targeted cancer therapies. UC Irvine News. June 2, 2026. Accessed June 8, 2026.